跳至主要内容
临床试验/NCT01815606
NCT01815606已完成不适用

Randomized Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm

AdventHealth2 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2013年2月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
AdventHealth
入组人数
51
试验地点
2
主要终点
Number of passes

研究概览

简要总结

This study will test two different needles for performing a biopsy of the pancreas during endoscopic ultrasound (EUS) procedures. Patients who are asked to participate in this study have a growth in the pancreas measuring greater than 35mm that needs a biopsy so that a diagnosis can be made. The biopsy can be performed using either a 19 or 25-Gauge needle. The purpose of this study is to compare which of the two needles is better for performing biopsies of the pancreas on masses that are greater than 35mm.

详细描述

Endoscopic Ultrasound-guided fine needle aspiration (EUS-FNA) can be performed using the 25, 22 or 19 gauge (G) needles. Randomized trials have shown that all three needles are safe and perform equally well. However, in a retrospective study, the diagnostic sensitivity of EUS-FNA for pancreatic masses that measured more than 35mm was less compared to smaller size masses. This is because larger size tumors have more necrosis and it is difficult to identify cancer cells in them to make a diagnosis. Therefore, more biopsies must be performed in larger size tumors to establish a diagnosis. In previous studies it has been shown that the larger 19G needles procure larger and better quality tissue. Therefore, our hypothesis is that, when a larger 19G needle is used to FNA tumors more than 35mm, a diagnosis can be achieved with fewer passes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Single (Participant)

入排标准

年龄范围
19 Years 至 89 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients referred to Florida Hospital Endoscopy Unit for assessment of pancreatic mass lesions greater than 35 mm on computed tomography (CT) that require FNA.

排除标准

  • Age < 19 years
  • Unable to safely undergo EUS for any reason
  • Coagulopathy (INR >1.6, Prothrombin Time >18secs, Thrombocytopenia <80,000 cells/ml)
  • Unable to consent
  • Non-English speaking patients
  • Participation in any other clinical trial (excluding registries or databases)

研究组 & 干预措施

19 Gauge needle biopsy

Active Comparator

biopsy with 19 gauge needle

干预措施: biopsy with 19 gauge needle (Procedure)

25 gauge needle biopsy

Active Comparator

biopsy with 25 gauge needle

干预措施: biopsy with 25 gauge needle (Procedure)

结局指标

主要结局

Number of passes

时间窗: Up to 12 months

The use of a 19G FNA needle reduces the number of passes required to establish a diagnosis in pancreatic tumors that are greater than 35mm in size. This translates to less sedation, faster patient recovery, better safety and time efficiency.

次要结局

  • Rate of Complication(Up to 12 months)

研究者

发起方
AdventHealth
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验